Interestingly, in a phase II trial testing the PARP-inhibitor Talazoparib as monotherapy for BRCA(Breast Related Cancer Antigen) 1/2 wild-type HER2- BC patients, authors reported that tumors which exhibited response or stability harbored gene mutations in the homologous recombination pathway, including PTEN gene mutations [41]. This evidence concerns the gene ERBB2 and breast cancer.